obesity and overweight clinical trials results

Bupropion versus placebo
Anderson, 2002	bupropion SR 300, or 400 mg/d. versus placebo	obese adults	double-blind Follow-up duration: 24 weeks
Croft, 2002	Bupropion, 300 mg for 44 wk versus Placebo	patients with major depression responder to open-label treatment with bupropion SR	double-blind Follow-up duration: 44 weeks
Jain, 2002	bupropion SR 300 mg/d versus Placebo	Obese adults (body mass index, 30 to 44 kg/m(2)) not currently meeting criteria for major depression but with depressive symptoms (Beck Depression Inventory score 10-30)	double-blind Follow-up duration: 26 weeks
Fluoxetine versus placebo
Breum, 1995	Fluoxetine, 60 mgfor 52 wk versus Placebo	aaaa
Connolly, 1995	fluoxetine 60 mg daily versus placebo	obese elderly patients over 60 years of age with Type 2 diabetes	double-blind
Darga, 1991	fluoxetine versus placebo	obese subjects	Follow-up duration: 52 weeks
Goldstein, 1994	Fluoxetine, 60 mgfor 52 wk versus Placebo	obese outpatients	double-blind Follow-up duration: 52-week
Gray, 1992	Fluoxetine, 60 mg for 6 mo versus Placebo	obese, type 2 non-insulin dependent diabetics being treated with insulin	double blind Follow-up duration: 24 weeks
Marcus, 1990	Fluoxetine, 60 mgfor 52 wk versus Placebo
Mendoza Espejo, 1995	Fluoxetine, 180 mgfor 6 mo versus Placebo
Michelson 50wk, 1999	Fluoxetine, 20 mgfor 50 wk versus Placebo
O’Kane, 1994	versus
liraglutide versus placebo
Astrup (NN8022-1807 ), 2009 NCT00422058	4 liraglutide doses (1.2 mg, 1.8 mg, 2.4 mg, or 3.0 mg daily) versus placebo	obese individuals without type 2 diabetes	double blind Follow-up duration: 20 weeks Europe
lorcaserin versus placebo
APD356-004, 2009	versus
BLOOM, 2010 NCT00395135	lorcaserin 10mg bid versus placebo		double-blind Follow-up duration: 52 weeks
BLOOM-DM (10mg bid), NCT00603291	lorcaserin 10 mg BID versus placebo	overweight and obese patients with type 2 diabetes mellitus managed with oral hypoglycemic agents	double-blind Follow-up duration: 52 weeks
BLOSSOM (10mg bid), 2009 NCT00603902	lorcaserin 10 mg twice daily versus placebo	obese and overweight patients	double blind Follow-up duration: 1 year USA
Orlistat versus placebo
Bakris, 2002	orlistat versus placebo	obese individuals with inadequately controlled hypertension.	double-blind Follow-up duration: 1-year
Broom, 2002	orlistat versus placebo	obese patients with cardiovascular risk	double-blind Follow-up duration: 54-week
Broom,, 2001	versus
Davidson, 1999	orlistat, 120 mg 3 times a day, for 52 weeks versus placebo	Obese adults (BMI 30-43 kg/m2)	double-blind Follow-up duration: 52 weeks US
Deerochanawong,, 2001	versus
Derosa, 2003	orlistat 120 mg TID versus placebo	obese patients with hypercholesterolemia	double-blind Follow-up duration: 1-year
Gotfredsen, 2001	versus
Halpern, 2003	orlistat (120 mg t.i.d.), versus placebo	Obese, non-insulin-dependent diabetic patients, aged 18-70 years old, with BMI > 27 kg/m2	Double-blind Follow-up duration: 24 weeks Latin-America
Hanefeld, 2002	orlistat 120 mg t.i.d. versus placebo	Overweight or obese adults (BMI >or= 28 kg/m2) with HbA1c of 6.5-11% and clinical type 2 diabetes	double-blind Follow-up duration: 48-week
Hauptman, 2000	60 mg of orlistat TID or 120 mg of orlistat TID, versus placebo	obese patients (BMI 30-44 kg/m2)	double-blind Follow-up duration: 1 year USA
Hill, 1999	30 mg orlistat, 60 mg orlistat, or 120 mg orlistat 3 times daily for 1 y versus placebo	Obese subjects who lost > or = 8% of their initial body weight during a 6-mo lead-in of a prescribed hypoenergetic diet (4180-kJ/d deficit) with no adjunctive pharmacotherapy	double-blind Follow-up duration: 1 year
Hollander, 1998	120 mg orlistat orally three times a day versus placebo	obese men and women with type 2 diabetes who were aged > 18 years, had a BMI of 28-40 kg/m2, and were clinically stable on oral sulfonylureas	double-blind Follow-up duration: 57-week
Karhunen, 2000	orlistat 120 mg t.i.d. versus placebo	obese subjects	double-blind Follow-up duration: 1 y.
Kelley, 2002	orlistat 120 mg three times a day versus placebo	overweight or obese adults (BMI 28-40 kg/m(2)) with type 2 diabetes treated with insulin alone or combined with oral agents, but with suboptimal metabolic control (HbA(1c) 7.5-12.0%)	double-blind Follow-up duration: 1-year
Krempf, 2005	orlistat 120 mg three times daily versus placebo	otherwise healthy, overweight patients aged 18-65 y (BMI >or=28 kg/m2	double-blind Follow-up duration: 18-month
Lindgarde, 2000	orlistat 120 mg three times daily versus placebo	obese adults (body mass index 28-38 kg m-2) with type 2 diabetes, hypercholesterolaemia and/or hypertension	double-blind Follow-up duration: 1 year Sweden
Lucas, 2003	versus
Micic, 1999	orlistat 120 mg three times daily versus placebo	obese patients (BMI > or = 30 kg/m2) with hyperlipidemia (LDL-cholesterol > or = 4, 2 mmol/l)	double-blind Follow-up duration: 24 weeks
Miles, 2002	120 mg orlistat t.i.d. versus placebo	overweight and obese patients with suboptimal control of type 2 diabetes	double-blind Follow-up duration: 1 year
Muls, 2001	orlistat 120 mg three times daily versus placebo	obese hypercholesterolemic patients, BMI between 27-40 kg/m2 and low-density-lipoprotein cholesterol, LDL-C, between 4.1-6.7 mmol/l	double-blind Follow-up duration: 24 week
Naumov, 2002	orlistat versus diet alone	patients with stable angina pectoris concomitant with obesity and hyperlipemia	open
Reaven, 2001	versus
Rissanen, 2001	orlistat 120 mg three times daily versus placebo	healthy obese women	double-blind Follow-up duration: 12-month
Rosenfalck, 2002	versus	obese patients
Rossner, 2000	orlistat (60 or 120 mg) three times a day versus Obese patients (body mass index 28 to 43 kg/m2)	Obese patients (body mass index 28 to 43 kg/m2)	double-blind Follow-up duration: 2-year
Shi Yi, 2001	versus
Sjostrom, 1998	orlistat 120 mg (three times a day) versus		double-blind Follow-up duration: 1 year Europe
Vidgren, 1999	120 mg of orlistat three times a day versus placebo	obese subjects	Follow-up duration: 1 year
PHEN/TPM high dose versus placebo
CONQUER (high-dose) (OB 303), 0 NCT00553787	PHEN/TPM 15/92 mg versus placebo		Follow-up duration: 56 weeks
OB 301 (high-dose), 0	PHEN/TPM 15/92 mg versus placebo		Follow-up duration: 28 weeks
OB 302 (high-dose), 0	PHEN/TPM 15/92 mg versus placebo		Follow-up duration: 56 weeks
PHEN/TPM low-dose versus placebo
OB 302 (low-dose), 0	PHEN/TPM 3.75/23 mg versus placebo		Follow-up duration: 56 weeks
PHEN/TPM mid-dose versus placebo
CONQUER (mid-dose) (OB 303), NCT00553787	PHEN/TPM 7.5/46 mg versus placebo		Follow-up duration: 56 weeks
OB 301 (mid-dose), 0	PHEN/TPM 7.5/46 mg versus placebo		Follow-up duration: 28 weeks
sibutramine versus placebo
SCOUT, 2010 NCT00234832	sibutramine versus placebo	overweight or obese patients with diabetes or a history of coronary or peripheral vascular disease or stroke, along with other CV risk factors	double blind Follow-up duration: 3.4 year
Sibutramine versus placebo
McMahon, 2002	versus
McMahon, 2000	versus
Smith, 2001	versus
tesofensine versus placebo
Astrup, 0	versus
Topiramate versus placebo
Bray, 2003	versus
Caterson, 2003	versus
Pud’homme, 2003	versus
Rissanen, 2003	versus
Stenlof, 2003	versus
Tonstad, 2003	versus